| Literature DB >> 25972269 |
Sweta Tiwari1, Henrik Schirmer2, Bjarne K Jacobsen1, Laila A Hopstock1, Audhild Nyrnes1, Geir Heggelund3, Inger Njølstad1, Ellisiv B Mathiesen4, Maja-Lisa Løchen1.
Abstract
OBJECTIVE: To investigate the association between echocardiographic measurements with emphasis on diastolic dysfunction and risk of atrial fibrillation (AF) in a population-based cohort study.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25972269 PMCID: PMC4518740 DOI: 10.1136/heartjnl-2015-307438
Source DB: PubMed Journal: Heart ISSN: 1355-6037 Impact factor: 5.994
Figure 1Flow chart, the Tromsø Study, 1994–2010. AF, atrial fibrillation.
Unadjusted baseline characteristics of women and men by incident clinical AF during follow-up
| Baseline characteristics | Women with | Men with | ||
|---|---|---|---|---|
| AF (n=193) | No AF (n=1043) | AF (n=269) | No AF (n=901) | |
| Age (years) | 66.4 (5.7) | 62.5 (6.0) | 64.2 (6.3) | 61.5 (6.4) |
| Systolic blood pressure (mm Hg) | 157.1 (23.8) | 145.2 (22.7) | 148.7 (22.7) | 145.3 (19.9) |
| Diastolic blood pressure (mm Hg) | 86.2 (14.4) | 82.2 (12.3) | 86.2 (12.5) | 85.4 (11.4) |
| Heart rate (beats/min) | 73.9 (13.7) | 75.2 (11.6) | 69.9 (13.2) | 71.4 (12.5) |
| Height (cm) | 161.6 (6.7) | 161.1 (6.1) | 175.3 (7.1) | 174.7 (6.6) |
| Body mass index (kg/m2) | 27.9 (5.2) | 26.0 (4.3) | 26.9 (3.6) | 25.9 (3.2) |
| BSA (m2) | 1.8 (0.2) | 1.7 (0.1) | 2.0 (0.2) | 1.9 (0.2) |
| Total cholesterol (mmol/L) | 7.13 (1.13) | 7.08 (1.24) | 6.58 (1.14) | 6.57 (1.19) |
| HDL cholesterol (mmol/L) | 1.67 (0.45) | 1.68 (0.42) | 1.40 (0.39) | 1.44 (0.40) |
| Alcohol, % (n) | ||||
| No alcohol | 37.2 (71) | 30.4 (315) | 13.8 (37) | 13.6 (122) |
| Low alcohol intake (0–4 times/month) | 61.3 (117) | 61.8 (641) | 65.7 (176) | 65.4 (587) |
| High alcohol intake (≥5 times/month) | 1.6 (3) | 7.9 (82) | 20.5 (55) | 21.0 (188) |
| Smoking, % (n) | ||||
| No Smoking | 48.2 (93) | 45.9 (479) | 21.2 (57) | 17.3 (156) |
| Previous smoking | 25.9 (50) | 24.6 (257) | 50.2 (135) | 47.3 (426) |
| Current smoking | 25.9 (50) | 29.4 (307) | 28.6 (77) | 35.4 (319) |
| Coffee (cups/day) | 4.9 (2.4) | 4.8 (2.7) | 5.7 (3.6) | 6.1 (3.7) |
| Physical activity, % (n) | 43.5 (84) | 53.4 (557) | 66.5 (179) | 67.4 (607) |
| Hypertension, % (n) | 80.8 (156) | 58.5 (610) | 70.6 (190) | 60.8 (548) |
| Antihypertensive treatment, % (n) | 25.9 (50) | 12.2 (127) | 22.4 (60) | 10.3 (92) |
| Coronary heart disease, % (n) | 6.3 (12) | 2.6 (27) | 15.3 (41) | 6.6 (59) |
| Valvular heart disease, % (n) | 1.0 (2) | 0.3 (3) | 1.1 (3) | 0.0 (0) |
| Heart failure, % (n) | 0.7 (1) | 0.3 (3) | 4.3 (9) | 1.5 (11) |
| Hypertrophy, % (n) | 2.0 (3) | 0.7 (6) | 3.8 (8) | 2.4 (18) |
| Diabetes, % (n) | 5.2 (10) | 2.4 (25) | 5.2 (14) | 2.6 (23) |
| Palpitations, % (n) | 38.1 (56) | 29.7 (260) | 24.4 (59) | 15.0 (124) |
| Thyroid disease, % (n) | 15.3 (21) | 10.5 (90) | 1.7 (4) | 1.9 (15) |
| LVM indexed by height (g/m1.7) | 77.3 (22.1) | 68.8 (17.8) | 90.4 (26.7) | 79.0 (21.3) |
| LVM indexed by BSA (g/m2) | 99.3 (26.3) | 90.8 (21.5) | 118.1 (32.9) | 105.0 (26.4) |
| LA size indexed by BSA (cm/m2) | 2.4 (0.4) | 2.2 (0.3) | 2.2 (0.3) | 2.1 (0.3) |
| E/A ratio | 0.96 (0.30) | 0.97 (0.25) | 1.01 (0.40) | 0.99 (0.27) |
| Deceleration time (dt) | 207.3 (49.5) | 196.4 (39.7) | 210.7 (48.1) | 206.4 (43.0) |
| Mitral Doppler groups, % (n) | ||||
| Group I | 71.7 (137) | 75.5 (773) | 69.2 (182) | 78.5 (695) |
| Group II | 2.6 (5) | 2.7 (28) | 4.9 (13) | 3.8 (34) |
| Group III | 22.0 (42) | 19.4 (199) | 24.0 (63) | 15.9 (141) |
| Group IV | 3.7 (7) | 2.3 (24) | 1.9 (5) | 1.7 (15) |
| Abnormal mitral Doppler flow | 28.3 (54) | 24.5 (251) | 30.8 (81) | 21.5 (190) |
The Tromsø Study, 1994–2010.
Mitral Doppler groups: Group I E/A ratio 0.75–1.5 and EDT ≥140 ms; group II E/A ratio >1.5 and EDT >140 ms; group III E/A ratio <0.75 and any EDT; group IV E/A ratio >0.75 and EDT <140 ms.
AF, atrial fibrillation; BSA, body surface area; EDT, E-wave deceleration time; HDL, high-density lipoprotein; LA, left atrium; LVM, LV mass.
HR (95% CI) for atrial fibrillation according to indexed left atrial (LA) size, mitral Doppler groups and mitral Doppler flow
| All | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|---|---|---|---|---|---|
| Indexed LA size | |||||
| 1 (<2.2) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| 2 (2.2–2.79) | 1.4 (1.1 to 1.7) | 1.6 (1.2 to 2.0) | 1.6 (1.3 to 2.0) | 1.6 (1.2 to 2.0) | 1.4 (1.1 to 1.8) |
| 3 (≥2.8) | 3.1 (2.1 to 4.4) | 4.2 (2.7 to 6.5) | 4.2 (2.7 to 6.5) | 4.1 (2.6 to 6.4) | 4.0 (2.5 to 6.4) |
| (p for trend <0.0001) | (p for trend <0.0001) | (p for trend <0.0001) | (p for trend <0.0001) | (p for trend <0.0001) | |
| Mitral Doppler groups | |||||
| Group I | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | – | 1 (Ref.) |
| Group II | 1.6 (1.0 to 2.7) | 1.8 (1.1 to 3.0) | 1.5 (0.9 to 2.6) | 1.6 (0.9 to 2.9) | |
| Group III | 1.1 (0.9 to 1.4) | 1.1 (0.9 to 1.4) | 1.2 (0.9 to 1.6) | 1.1 (0.9 to 1.5) | |
| Group IV | 1.7 (1.0 to 3.0) | 1.5 (0.8 to 3.1) | 1.5 (0.7 to 2.9) | 1.2 (0.5 to 3.0) | |
| (p Value for trend 0.103) | (p Value for trend 0.141) | (p Value for trend 0.051) | (p Value for trend 0.240) | ||
| Abnormal mitral Doppler flow | 1.2 (1.0 to 1.5) | 1.2 (1.0 to 1.5) | – | 1.3 (1.0 to 1.6) | 1.2 (0.9 to 1.5) |
| (Group II–IV) | (p Value 0.081) | (p Value 0.086) | (p Value 0.034) | (p Value 0.159) | |
The Tromsø Study, 1994–2010.
Model 1: adjusted for age and sex.
Model 2: as Model 1+height, body mass index, hypertension, diabetes, palpitation.
Model 3: as Model 2+abnormal mitral Doppler flow (only in indexed LA size), LA size (only in mitral Doppler groups and flow).
Model 4: as Model 2+mitral Doppler groups (only in indexed LA size) or LA size (only in mitral Doppler groups and flow).
Model 5: as Model 2, participants with coronary heart disease, valvular heart disease, heart failure or hypertrophy at baseline excluded.
Mitral Doppler groups: Group I E/A ratio 0.75–1.5 and E-wave deceleration time (EDT >140 ms; group II E/A ratio >1.5 and EDT >140 ms; group III E/A ratio <0.75 and any EDT; group IV E/A ratio >0.75 and EDT <140 ms.
Ref; reference.
Figure 2Kaplan–Meier curves for atrial fibrillation (AF): (a) categories of left atrial (LA) size and (b) categories of mitral Doppler indices. The Tromsø Study, 1994–2010.
Figure 3Kaplan–Meier curves for atrial fibrillation (AF) categories of left atrial (LA) size and mitral Doppler indices combined. The Tromsø Study, 1994–2010. Group 1=LA size <2.2 cm/m2 and normal mitral Doppler indices (n=947). Group 2=LA size <2.2 cm/m2 and abnormal mitral Doppler indices (n=294). Group 3=LA size 2.2–2.79 cm/m2 and normal mitral Doppler indices (n=720). Group 4=LA size 2.2–2.79 cm/m2 and abnormal mitral Doppler indices (n=227). Group 5=LA size ≥2.8 cm/m2 and normal/abnormal mitral Doppler indices (n=92).
Sex-specific HR (95% CI) for atrial fibrillation according to left atrial (LA) size, and mitral Doppler flow and left atrial size combined
| Indexed left atrial size | p Value for trend | |||
|---|---|---|---|---|
| 1 (<2.2) | 2 (2.2 to 2.79) | 3 (≥2.8) | ||
| Women | ||||
| Events (n=177) | n=61 | n=89 | n=27 | |
| Model 1 | 1 (Ref.) | 1.5 (1.1 to 2.1) | 3.0 (1.9 to 4.9) | <0.0001 |
| Model 2 | 1 (Ref.) | 1.6 (1.1 to 2.3) | 4.5 (2.6 to 8.0) | <0.0001 |
| Model 3 | 1 (Ref.) | 1.5 (1.0 to 2.3) | 4.4 (2.4 to 8.0) | <0.0001 |
| Men | ||||
| Events (n=259) | n=128 | n=119 | n=12 | |
| Model 1 | 1 (Ref.) | 1.4 (1.1 to 1.8) | 3.0 (1.6 to 5.5) | 0.001 |
| Model 2 | 1 (Ref.) | 1.5 (1.2 to 2.0) | 3.6 (1.7 to 7.5) | <0.0001 |
| Model 3 | 1 (Ref.) | 1.3 (1.0 to 1.8) | 3.3 (1.3 to 8.3) | 0.024 |
| All | ||||
| Events (n=436) | n=189 | n=208 | n=39 | |
| Mitral Doppler flow | ||||
| Normal | 1 (Ref.) | 1.4 (1.1 to 1.7) | 3.1 (2.1 to 4.8) | <0.0001* |
| Abnormal | 1.2 (0.9 to 1.7) | 1.8 (1.3 to 2.4) | 3.5 (1.8 to 6.7) | |
| Mitral Doppler flow | ||||
| Normal | 1 (Ref.) | 1.5 (1.2 to 2.0) | 4.8 (2.9 to 7.8) | <0.0001* |
| Abnormal | 1.3 (0.9 to 1.8) | 2.1 (1.5 to 3.0) | 3.7 (1.6 to 8.7) | |
The Tromsø Study, 1994–2010.
*p Value for trend is calculated for six groups of LA size and mitral Doppler flow combined. Description can be found in the Methods section.
Model 1: adjusted for age and sex (not in sex-specific models).
Model 2: as Model 1+height, body mass index, hypertension, diabetes, palpitation.
Model 3: as Model 2, participants with coronary heart disease, valvular heart disease, heart failure or hypertrophy at baseline excluded.
Model 4: as Model 1.
Model 5: as Model 2.
Mitral Doppler flow—normal: E/A ratio 0.75–1.5 and E-wave deceleration time (EDT >140 ms; abnormal: E/A ratio <0.75 or >1.5 or EDT <140 ms.
Ref; reference.